Assembly biosciences presents new data highlighting long-acting herpes simplex virus candidate abi-5366 and genital herpes prevalence and treatment patterns at the 2025 escmid congress

– clinical and preclinical data supporting dosing profile and tolerability for abi-5366, a novel long-acting helicase-primase inhibitor candidate, featured in two poster presentations –
ASMB Ratings Summary
ASMB Quant Ranking